(Date:5/16/2008)...international, multi-center registry presented at ...stCall/ -- Boston Scientific,Corporation (NYSE: B...ional,multi-center patient registry documenting t...Direct Visualization System will be presented at,D...y 17-22 in San Diego,CA. Registry results will be...
(Date:5/16/2008)...N.C., May 16 /- Campbell Alliance, th...in the pharmaceutical and biotech,industry, today ...ociety of,Pharmaceutical and Biotech Trainers (SPB... the Orlando World Center Marriott in Orlando, Flo...hmidt, Vice President in the,Sales Practice, will ...
(Date:5/16/2008)..., May 16 /- Alba Therapeutics Corpora...omized its first patient in a,twelve-week Phase II... of,intestinal barrier dysfunction, for the treatm...he global multi-center, randomized, double-blind,...l and histological,efficacy, safety and tolerabili...
(Date:5/16/2008)...May 16 / Oncolytics Biotech...t an abstract covering interim,results of a Phase ...th,sarcomas metastatic to the lung is available on...website at http://www.asco.org and on the Oncoly.... The abstract is entitled "A Phase II,Study of In...
Breaking Biology Technology:Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R) 2Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R) 3Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R) 4Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R) 5Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference 2Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference 3Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 2Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 3Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting 2...RNA , and Protein Isolati...RNA Isolation System, , PARIS, ..., total RNA and native protein ...mple. Cultured cells and tissues that are either f... RNA stabilization reagents such as , ...
... algorithm designed by Cenix BioScience, with who...e wide siRNA library, represents a major improveme...by Tuschl and colleagues. On average, ~50% , ...(target sites beginning , with AA, 3, UU ov...ands, , ~50% G/C content; 1-3) provide at l...
... Dicer and Escherichia coli RNase...cleave long dsRNA, producing siRNA cocktails that ...ne silencing (1-6). Dicer is an , ...s and is the , enzyme responsib... endogenous RNAi pathway. The siR...
...ed Primary Antibodies , Gene...ther you are starting out in siRNA , ...appreciate the , convenience of... controls. Each Silencer gene specific siR...eady-to-use chemically synthesized and gel , ...
Other Biology Technology:Efficient Cellular Fractionation for RNA , and Protein Isolation 2Efficient Cellular Fractionation for RNA , and Protein Isolation 3Efficient Cellular Fractionation for RNA , and Protein Isolation 4Efficient Cellular Fractionation for RNA , and Protein Isolation 5Efficient Cellular Fractionation for RNA , and Protein Isolation 6Efficient Cellular Fractionation for RNA , and Protein Isolation 7Designing a Better siRNA 2Designing a Better siRNA 3Designing a Better siRNA 4Designing a Better siRNA 5Dicer vs. RNase III for Preparation of siRNA Cocktails 2Dicer vs. RNase III for Preparation of siRNA Cocktails 3Control Your siRNA Research 2Control Your siRNA Research 3(Date:5/15/2008)...,, A team of Penn State researchers has develo...gate the organization and function of two of the m...he cytoplasm--the gelatinous fluid that surrounds ...ad to the creation of new drugs that take advantag...e development of diseases. The team,s findings wi...
(Date:5/15/2008)...,, The human race was divided into two separat...existence, says a Tel Aviv University mathematicia...rsh conditions may have caused and maintained the ...ol of Mathematical Sciences at Tel Aviv University...bam Medical Center to analyze African DNA. Their g...
(Date:5/15/2008)... Argonne, Ill. (May 15, 2008) Argonne National La...(MOU) with Savannah River National Laboratory (SRN...tal management research projects in support of cri... important national priorities. , "The MOU allow...earch," Argonne director Robert Rosner said. "Argo...
(Date:5/15/2008)... Stowers Institute researchers Karen Staehling-Ham...y, and Olivier Pourqui, Ph.D., Investigator, colla...how that genes known to cause spinal mutations in ...nt role in human patients with congenital vertebra...today on the Web site of the American Journal of H...
Breaking Biology News(10 mins):Simple model cell is key to understanding cell complexity 2Long lost sisters 2Argonne-SRNL agreement supports critical DOE, national priorities 2Stowers Institute researchers identify gene linked to vertebral defects in patient populations 2Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 1Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 2Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 3UD plant biologists uncover top wetland plants hidden weapon 778 1UD plant biologists uncover top wetland plants hidden weapon 778 2UD plant biologists uncover top wetland plants hidden weapon 778 3Anti Cholesterol Drugs Help Prevent Lung Decline 3548 1Anti Cholesterol Drugs Help Prevent Lung Decline 3548 2Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo 28TM 29 1235 1Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo 28TM 29 1235 2Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo 28TM 29 1235 3Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo 28TM 29 1235 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo 28TM 29 1235 5Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo 28TM 29 1235 6Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo 28TM 29 1235 7Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2
...cro;L ,• High specific activity and process... 'A' overhang ,• Processes ,A thermosta...ty in primer extension and other molecular biology..., each lot has been functionally tested for maxima...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I
...emically modified form of AmpliTaq® DNA Polyme...enzyme, the enzyme is inactive. During set-up and ...on is going through non-optimal annealing temperat...mis-primed primers are not extended. Once the reac...
Biology Products: